Related Experiment Video
Updated: Aug 13, 2025
Evaluating Autophagy Levels in Two Different Pancreatic Cell Models Using LC3 Immunofluorescence
Published on: April 28, 2023
The Anti-Tubercular Aminolipopeptide Trichoderin A Displays Selective Toxicity against Human Pancreatic Ductal
Johanes K Kasim1,2, Jiwon Hong1,2,3,4, Anthony J R Hickey1,2
1School of Biological Sciences, The University of Auckland, 3A Symonds Street, Auckland 1010, New Zealand.
Abstract:
Pancreatic ductal adenocarcinoma remains a highly debilitating condition with no effective disease-modifying interventions. In our search for natural products with promising anticancer activity, we identified the aminolipopeptide trichoderin A as a potential candidate. While it was initially isolated as an antitubercular peptide, we provide evidence that it is also selectively toxic against BxPC-3 and PANC-1 human pancreatic ductal adenocarcinoma cells cultured under glucose deprivation. This has critical implications for the pancreatic ductal adenocarcinoma, which is characterized by nutrient deprivation due to its hypovascularized network. We have also successfully simplified the trichoderin A peptide backbone, allowing greater accessibility to the peptide for further biological testing. In addition, we also conducted a preliminary investigation into the role of peptide lipidation at the N-terminus. This showed that analogues with longer fatty acyl chains exhibited superior cytotoxicity than those with shorter acyl chains. Further structural optimization of trichoderin A is anticipated to improve its biological activity, whilst ongoing mechanistic studies to elucidate its intracellular mechanism of action are conducted in parallel.
Insights
Trichoderin A, an aminolipopeptide, shows selective toxicity against pancreatic cancer cells under glucose deprivation. Simplified analogues and lipidation modifications enhance its potential as an anticancer agent.
Area of Science:
- Biochemistry
- Oncology
- Natural Products Chemistry
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a devastating cancer with limited treatment options.
- PDAC is characterized by a nutrient-deprived microenvironment due to poor vascularization.
- Natural products are a promising source for novel anticancer drug discovery.
Purpose of the Study:
- To investigate the anticancer potential of trichoderin A against pancreatic ductal adenocarcinoma cells.
- To explore the effects of structural modifications on trichoderin A's cytotoxicity.
- To evaluate trichoderin A's efficacy under nutrient-deprived conditions relevant to PDAC.
Main Methods:
- Selective toxicity assays on BxPC-3 and PANC-1 human pancreatic cancer cell lines.
- Culturing cells under glucose deprivation to mimic the tumor microenvironment.
- Synthesis and evaluation of simplified trichoderin A backbone analogues.
- Preliminary investigation of N-terminal lipidation effects on cytotoxicity.
Main Results:
- Trichoderin A demonstrated selective toxicity against pancreatic ductal adenocarcinoma cells under glucose deprivation.
- Simplified trichoderin A analogues were successfully synthesized, improving accessibility.
- Analogues with longer N-terminal fatty acyl chains exhibited enhanced cytotoxicity.
- The findings highlight trichoderin A's potential in targeting nutrient-deprived pancreatic tumors.
Conclusions:
- Trichoderin A is a promising candidate for pancreatic ductal adenocarcinoma therapy, particularly in nutrient-deprived conditions.
- Structural simplification and lipidation offer avenues for optimizing trichoderin A's anticancer activity.
- Further research into trichoderin A's mechanism of action and optimized analogues is warranted.
More Related Videos
06:21Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012